Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMAB362

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
16Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant… Expand
Is this relevant?
2018
2018
INTRODUCTION IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to… Expand
Is this relevant?
2016
2016
LBA4001Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ… Expand
Is this relevant?
Review
2016
Review
2016
In recent years, various new agents have been investigated for the treatment of advanced gastric cancer (AGC). The anti-HER2… Expand
  • table 1
  • table 2
Is this relevant?
2015
2015
e15079 Background: IMAB362 is the first-in-class monoclonal antibody against the tight junction molecule claudin 18.2 (CLDN18.2… Expand
Is this relevant?
2014
2014
The majority of pancreatic neoplasms are characterized by a generally lethal progress within a short period of time after primary… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on… Expand
Is this relevant?
2014
2014
Pancreatic ductal adenocarcinoma (PDAC), the most frequent subtype (>80%) of pancreatic cancer (PC) is characterized by a… Expand
Is this relevant?
2013
2013
4080 Background: IMAB362 is a monoclonal antibody targeting isoform 2 of the tight junction component claudin 18 (CLDN18.2), a… Expand
Is this relevant?